STOCK MARKET BSE NSE

Will Centre have Rs 80,000 crore for distribution of COVID-19 vaccine, asks Serum Institute CEO

The central health ministry official said that they have not received any official proposal from the institute regarding mass production, procurement, and distributions of the vaccine.

Published: 26th September 2020 09:05 PM  |   Last Updated: 26th September 2020 09:33 PM   |  A+A-

Serum Institute CEO Adar Poonawalla

Serum Institute CEO Adar Poonawalla (Photo | PTI)

By Express News Service

MUMBAI: The Serum Institute of India (SII) has asked the Centre if they will have Rs 80,000 crore in their kitty to buy and distribute the Oxford Covid-19 vaccine next year. 

Adar Poonawalla, CEO of SII which is producing the potential coronavirus vaccine with Oxford University and British pharmaceutical company AstraZeneca, raised the question on Twitter Saturday: “Quick question; will the government of India have Rs 80,000 crores available, over the next one year? Because that's what @MoHFW_INDIA needs, to buy and distribute the vaccine to everyone in India. This is the next concerning the challenge we need to tackle.” 

He further says, “I ask this question, because we need to plan and guide, vaccine manufacturers both in India and overseas to service the needs of our country in terms of procurement and distribution.”

The central health ministry official was surprised by the tweet of Poonawlla. They said that they have not received any official proposal from the Serum Institute of Indian regarding mass production, procurement, and distributions of the vaccine. "We are also clueless about this tweet," they said requested anonymity.

When contacted, Adar Poonawalla's office refused to elaborate on the intention behind sharing this information in the public domain. "Whatever Mr Poonawalla wanted to say, he had tweeted it and that is only information from their side."

More than 150 potential vaccines are being developed and tested globally. Candidates from Moderna Inc, Pfizer Inc, and AstraZeneca Plc are already in late-stage trials.

Earlier, SII was asked by the drug regulator to pause the Oxford vaccine trial in India after an adverse reaction was reported abroad.



Comments(1)

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

  • APK

    It seems this guy Poonawalla is being really cheeky here. He wants to avoid tough price negotiation with the government and wants to profit big time from this vaccine. By giving out the price tag publicly he has tried to push the government into accepting the price - or else the public might think the government is bickering about the price instead of saving its citizens.
    22 days ago reply
IPL_2020
flipboard facebook twitter whatsapp